Publications by authors named "Pascal Do"

Claim this Profile
I
Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer.
Jean Cabon, Delphine Lerouge, Sebastien Thureau, Jacques Balosso, Marin Guigo, Edouard Dantoing

Front Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Pascal Do

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Dabrafenib Plus Trametinib Combination in Patients with V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019.
Jean-Bernard Auliac, Sophie Bayle, Pascal Do, Gwenaëlle Le Garff, Magali Roa

Cancers (Basel)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Pascal Do

Cancer Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier

Lung Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14.
Jean-Bernard Auliac, Pascal Dô, Sophie Bayle, Hélène Doubre, Florent Vinas

Adv Ther· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
Benjamin Houdu, Charline Lasnon, Idlir Licaj, Guy Thomas, Pascal Do

Eur J Nucl Med Mol Imaging· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
Benjamin Houdu, Charline Lasnon, Idlir Licaj, Guy Thomas, Pascal Do

Eur J Nucl Med Mol Imaging· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô

Lancet Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.
Paul Lesueur, Alexandre Escande, Juliette Thariat, Enora Vauléon, Isabelle Monnet

Cancer Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
Jaafar Bennouna, Fabrice Barlesi, Pascal Do, Patrick Dumont, Jacques Cadranel

ESMO Open· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy.
Guillaume Le Baut, Jean-Marc Guilloit, Vincent Leprince, Yann Ollivier, Catherine Dubos-Arvis, Pascal Do, Ludovic Loge

J Gastrointest Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life experience of ceritinib in crizotinib-pretreated advanced non-small cell lung cancer patients.
Jacques Cadranel, Alexis B Cortot, Hervé Lena, Bertrand Mennecier, Pascal Do

ERJ Open Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.
Simon Baldacci, Julien Mazieres, Pascale Tomasini, Nicolas Girard, Florian Guisier

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
Christos Chouaid, Laura Luciani, Katell LeLay, Pascal Do, Jaafar Bennouna

J Thorac Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between lung cancer somatic mutations and occupational exposure in never-smokers.
Christophe Paris, Pascal Do, Bénédicte Mastroianni, Adrien Dixmier, Patrick Dumont

Eur Respir J· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Leena Gandhi, Sai-Hong Ignatius Ou, Alice T Shaw, Fabrice Barlesi, Anne-Marie C Dingemans, Dong-Wan Kim, Pascal Do, Walter Bordogna

Eur J Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer.
Delphine Dumont, Pascal Dô, Delphine Lerouge, Gaëtane Planchard, Marc Riffet

Am J Case Rep· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
Benoît Dupont, Delphine Mariotte, Audrey E Dugué, Bénédicte Clarisse, Jean-Michel Grellard, Cristian Moldovan, Pascal Do

Br J Clin Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.
Charline Lasnon, Thibault Salomon, Cédric Desmonts, Pascal Dô, Youssef Oulkhouir

Ann Nucl Med· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer.
Charline Lasnon, Mohamed Majdoub, Brice Lavigne, Pascal Do, Jeannick Madelaine

Eur J Nucl Med Mol Imaging· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
Alison C Johnson, Pascal Dô, Nicolas Richard, Catherine Dubos, Jean Jacques Michels

Lung Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
Alain Vergnenegre, Bartomeu Massuti, Filippo de Marinis, Enric Carcereny, Enriqueta Felip, Pascal Do

J Thorac Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
Marion Sassier, Audrey Emmanuelle Dugué, Bénédicte Clarisse, Paul Lesueur, Virginie Avrillon, Pascal Do

Lung Cancer· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.
Sébastien Couraud, Pierre-Jean Souquet, Christophe Paris, Pascal Dô, Hélène Doubre

Eur Respir J· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis